Amanote Research
Register
Sign In
Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer
Cancer
- United States
doi 10.1002/cncr.32088
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
April 1, 2019
Authors
Carrie Printz
Publisher
Wiley
Related search
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE
Cancer
Cancer Research
Oncology
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Meta-Analysis
Scientific Reports
Multidisciplinary
FEN1 Knockdown Improves Trastuzumab Sensitivity in Human Epidermal Growth Factor 2‑positive Breast Cancer Cells
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy as (Neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Ado-Trastuzumab Emtansine Targets Hepatocytes via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity
Molecular Cancer Therapeutics
Cancer Research
Oncology
Patients’ Preferences for Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Treatments in Japan
Breast Cancer
Nuclear Medicine
Radiology
Pharmacology
Oncology
Imaging
Medicine
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Pertuzumab in Human Epidermal Growth-Factor Receptor 2-Positive Breast Cancer: Clinical and Economic Considerations
International Journal of Women's Health
Gynecology
Oncology
Midwifery
Maternity
Obstetrics
Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer
Expert Opinion on Biological Therapy
Drug Discovery
Clinical Biochemistry
Pharmacology
